Case Overview

In a significant ruling for the liquid biopsy and oncology diagnostics sector, the U.S. Court of Appeals for the Federal Circuit affirmed a district court’s grant of a preliminary injunction in favor of **Natera, Inc.** against **NeoGenomics Laboratories, Inc.** (Case No. 24-1324). Decided on July 12, 2024, just 190 days after filing, the appellate court found no abuse of discretion in the lower court’s decision to restrain NeoGenomics’ accused genomic testing activities—a ruling with immediate commercial consequences for both companies and broader implications for **liquid biopsy patent litigation**.

At the heart of the dispute are two foundational genomic diagnostics patents—US11530454B2 and US11519035B2—covering methods for detecting mutations and ploidy in chromosomal segments and simultaneous amplification of target loci. For patent attorneys tracking Federal Circuit precedent, IP professionals monitoring diagnostics licensing trends, and R&D teams navigating freedom-to-operate risks in next-generation sequencing, this case delivers critical signals worth analyzing closely.

The Parties

Patents at Issue

This landmark case involved two foundational genomic diagnostics patents protecting upstream molecular biology techniques with broad commercial relevance across oncology diagnostics platforms. These patents are registered with the U.S. Patent and Trademark Office (USPTO) and cover critical methods for liquid biopsy technologies.

• • US11530454B2 — Methods for detecting mutations and ploidy in chromosomal segments.
• • US11519035B2 — Methods for simultaneous amplification of target loci.

The Verdict & Legal Analysis

Outcome

The Federal Circuit **affirmed** the district court’s grant of a **preliminary injunction** in Natera’s favor. NeoGenomics’ appeal was dismissed. The court reviewed the district court’s ruling under the deferential **abuse of discretion** standard—the appropriate framework for preliminary injunction appeals—and found that standard was not met by NeoGenomics’ arguments. No specific damages award was disclosed at this stage, as the appeal concerned preliminary injunctive relief rather than a final merits adjudication.

Key Legal Issues

The appellate panel’s decision rested on several key determinations:

• Sufficiency of the Preliminary Injunction Standard: To obtain a preliminary injunction in patent cases, the movant must demonstrate: (1) likelihood of success on the merits, (2) likelihood of irreparable harm absent an injunction, (3) balance of hardships favoring the movant, and (4) that the public interest would not be disserved. The Federal Circuit’s affirmance signals the district court’s analysis of these factors—particularly likelihood of success on patent validity and infringement—was legally sound.
• Technical Complexity and Judicial Management: The court’s explicit acknowledgment of “highly technical” subject matter and the parties’ overly expansive litigation strategies is noteworthy. The district court was credited for “deftly parsing through excessive arguments” to reach a fair resolution—language that implicitly signals approval of judicial efficiency measures in complex biotech patent cases.
• Public Interest Balancing: The appellate court affirmed the district court’s finding that the preliminary injunction’s negative impact on public interest was appropriately minimized. In diagnostics cases, public interest arguments—particularly patient access to testing—are frequently deployed as equitable defenses. The district court’s careful handling of this factor, affirmed on appeal, sets a useful benchmark.
• NeoGenomics’ Remaining Arguments Found Unpersuasive: The Federal Circuit’s language—that remaining arguments were considered and found unpersuasive without detailed elaboration—suggests NeoGenomics’ appellate strategy failed to identify reversible legal error in the district court’s framework, a high bar to clear under abuse of discretion review.

This decision carries meaningful precedential weight for genomic diagnostics patent litigation, reinforcing the Federal Circuit’s deference to district courts in technically complex preliminary injunction proceedings.